CN106800588A - A kind of peptide and its application - Google Patents
A kind of peptide and its application Download PDFInfo
- Publication number
- CN106800588A CN106800588A CN201510847635.XA CN201510847635A CN106800588A CN 106800588 A CN106800588 A CN 106800588A CN 201510847635 A CN201510847635 A CN 201510847635A CN 106800588 A CN106800588 A CN 106800588A
- Authority
- CN
- China
- Prior art keywords
- arg
- cell
- peptide
- tyr
- cosmetics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 41
- YUIGJDNAGKJLDO-JYJNAYRXSA-N Arg-Arg-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YUIGJDNAGKJLDO-JYJNAYRXSA-N 0.000 claims abstract description 45
- 230000009758 senescence Effects 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims description 48
- 230000032683 aging Effects 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 3
- 229910001721 mellite Inorganic materials 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 abstract description 39
- 238000002474 experimental method Methods 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 24
- 230000035755 proliferation Effects 0.000 abstract description 13
- 230000022131 cell cycle Effects 0.000 abstract description 11
- 238000001514 detection method Methods 0.000 abstract description 11
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 abstract description 6
- 108010087230 Sincalide Proteins 0.000 abstract description 5
- 238000010609 cell counting kit-8 assay Methods 0.000 abstract description 5
- 230000004663 cell proliferation Effects 0.000 abstract description 5
- 230000002500 effect on skin Effects 0.000 abstract description 4
- 210000002950 fibroblast Anatomy 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 84
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 55
- 210000003491 skin Anatomy 0.000 description 39
- 239000000047 product Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 28
- 235000019441 ethanol Nutrition 0.000 description 20
- 210000004209 hair Anatomy 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 238000003032 molecular docking Methods 0.000 description 15
- 150000001875 compounds Chemical group 0.000 description 14
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000000370 acceptor Substances 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 238000004140 cleaning Methods 0.000 description 8
- 238000004043 dyeing Methods 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000007792 addition Methods 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000005138 cryopreservation Methods 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 238000012900 molecular simulation Methods 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010019160 Pancreatin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- -1 mildy wash Substances 0.000 description 4
- 229940055695 pancreatin Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006059 cover glass Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000806 elastomer Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000003041 virtual screening Methods 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000003483 aging Methods 0.000 description 2
- 239000013040 bath agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 210000000630 fibrocyte Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000088 lip Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000012805 post-processing Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000008257 shaving cream Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241001482108 Alosa pseudoharengus Species 0.000 description 1
- 206010058646 Arcus lipoides Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 206010067632 Cartilage atrophy Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010016029 Face oedema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000587161 Gomphocarpus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 241001446187 Kermes Species 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 206010071308 Melanocytic hyperplasia Diseases 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000000875 Spinal Curvatures Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 201000000351 arcus senilis Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 210000000968 fibrocartilage Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- CXORMDKZEUMQHX-UHFFFAOYSA-N kermesic acid Chemical compound O=C1C2=C(O)C(O)=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C CXORMDKZEUMQHX-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000027906 leg weakness Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000013113 molecular simulation experiment Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 230000004995 multiple fission Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000002267 nissl body Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000000455 protein structure prediction Methods 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 210000003859 smegma Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to albumen field, more particularly to a kind of peptide and its application.During the present invention by tripeptides Arg-Arg-Tyr by acting on HSF, CCK-8 proliferation experiments, Edu methods detection cell proliferation experiment, the experiment of flow cytomery cell cycle are carried out to HSF.It is experimentally confirmed that tripeptides Arg-Arg-Tyr can effectively facilitate proliferation of human dermal fibroblasts, increase S+G2M phase proportions, it is used for skin senescence prevention or treatment determined curative effect, Small side effects, therefore has important practical significance.
Description
Technical field
The present invention relates to albumen field, more particularly to a kind of peptide and its application.
Background technology
Aging, is the process for referring to that each organ dysfunction of body is universal, gradually reducing.Aging has two kinds not
Same situation, a kind of is the physiological aging for occurring under normal circumstances;Another kind is the pathology that disease causes
Property aging.It is a kind of natural law.But, when people use good habits and customs and hygienic measures,
Just can effectively anti-aging, improve the quality of living.Theory of traditional Chinese medical science thinks, the growth of human body, development,
Aging is in close relations with the prosperity and decline of function and meridian qi and blood.When body insufficiency of vital energy and blood, QI of channels and collaterals fortune
Capable not smooth, function goes down, negative and positive disequilibrium, can cause and accelerate aging, shows as spirit
Depressed, forgetful, shape is cold, and limb is cold, few dormancys of difference of receiving, waist-leg weakness, hair take off tooth shake, shortness of breath and fatigue, very then
Face edema etc..Over the past thousands of years, people are exploring the secret of good health and a long life always, full of residing permanently to the youth,
The yearning promoted longevity.
The mechanism for exploring aging generation is both an ancient problem, is again a brand-new scientific research field,
In the very long history development procedure of medical science, it is believed that proposing the hypothesis of hundreds of agings altogether.Ancestral
State's medical science have accumulated rich experience in terms of anti-aging, it is proposed that " imbalance of yin and yang is said ", " internal organs void declines ",
" energy loss theory " etc., is impregnated with the understanding to nature macroscopic view.External ancient medicine man and wise man
Scholar also explains aging from different perspectives, proposes warm theory, entropy theory, abrasion theory, oneself is poisoned
Theory etc., plays a positive role for people's understanding aging.But because of historical conditions and the limit of scientific level
System, these theories have significant limitation.
Modern study shows, skin senescence is reflected in cellular level as cell ageing, and fibroblast
It is the bulk composition in corium, its aging and the change of biological characteristics cause skin aging to occur
Major reason.At present, be all mostly by cosmetics for external use add EGF (EGF) come
Improve skin, it has certain effect.But because the reason such as technology, the production and supply of EGF raw materials
It is difficult to meet increasing need, the price of EGF remains high always, not only seriously constrains EGF
Clinical research and clinical practice, also limit further genralrlization of the EGF cosmetics in consumer groups.
Therefore, a kind of efficient EGF-R ELISA (EGFR) activating molecules are developed not only with huge
Economic worth, also provides most basic guarantee for EGF researchs and develops broader practice prospect.
The content of the invention
In view of this, the present invention provides a kind of peptide and its application.The peptide can effectively facilitate skin into fiber finer
Born of the same parents breed, anti aging effect, at the same also have it is easy to use, raw material sources extensively, it is cheap, drop
The toxicity of low cosmetics, has a safety feature.
In order to realize foregoing invention purpose, the present invention provides following technical scheme:
The invention provides a kind of peptide, including:
(I), the amino acid sequence of Arg-Arg-Tyr;Or
(II), (I) described amino acid sequence is substituted, lacks or adds one or more amino acid and obtains
Amino acid sequence, and with the same or analogous amino acid sequence of amino acid sequence function shown in (I)
Row;
(III) and (I) or (II) described sequence at least 80% homology amino acid sequence;
The amino acid number of the peptide is 3~5.
In some specific embodiments of the invention, the amino acid of the addition is selected from Trp or Phe.
In other specific embodiments of the invention, the amino acid sequence of the peptide is Arg-Arg-Tyr.
The answering in the cosmetics for being used for preventing and/or treat aging are prepared present invention also offers the peptide
With.
In the present invention, the aging is embodied on the whole:Height declines, spinal curvature, and skin loses
Elasticity is gone, face gauffer increases, local skin, particularly face, hand etc., it is seen that pigmentation are in
The brown spot for differing in size, referred to as senile plaque expelling.Sweat gland, smegma are reduced makes dry skin, lacks
Weary gloss.Beard and hair is greyish white, and the domain or half often occurs in alopecia even bald, ptosis, peripheral cornea
Ring white herring bone, is called arcus senilis (or old bow), caused by being lipidosis.Loss of tooth, but time
Vary with each individual sooner or later.In terms of behavior, the elderly is slow in reacting, and stride is slow, and facial expression is gradually stayed
Stagnant, failure of memory notes not concentrating, and language often likes repetition.Hypopsia, tends to long sight.Hearing
Also easily degenerate.
In the present invention, the aging is embodied in from tissue with organ level:Skeletal system --- bone group
Knit with age aging it is calcareous decrescence, bone brittleness, easily fracture, wound healing is also than slow at an early age.
Joint motion ability declines, and is susceptible to suffer from the fibrocartilage pad between arthritis, spinal vertebral due to cartilage atrophy
It is thinning, cause backbone to shorten, this is that the elderly becomes a short reason.Skin --- old human dermis' breast
Head step-down, makes epidermis be flattened with dermis interface, and epidermis is thinning, and corium reticular fibre is reduced, elastomer
Elasticity and easy fracture are gradually lost, collagenous fibres update slack-off, and old fiber is in the majority, and collagen cross-linking increase makes
The elasticity reduction of collagenous fiber network.Cutis laxa, no longer tightly invests sub-dermal structures, transparent in cytoplasm
Matter acid is reduced and chondroitin sulfate increases relatively, makes the reduction of corium water content, and subcutaneous fat is reduced, sweat gland,
, there is senile plaque expelling due to local melanocytic hyperplasia in sebaceous gland atrophy.Muscle --- the elderly's flesh weight with
The ratio between body weight declines.Moisture, sodium and chloride outside myocyte have increase tendency, intracellular potassium content
Then there is decline to be inclined to, additionally, muscle fibre quantity declines, diameter reduces, and whole muscle is seemed atrophy.
This damped exponential model is different because function is different, and ST tends in different quick muscles or mixing flesh
Extension, and ST tends to shorten in slow constrictor, this can influence the phase interaction of different motion unit
With reduction muscle group coordinates the validity of mutual aid, it is likely that this is the hypodynamic reason of old man's flesh.When
So, the Aging changes of motor unit are also not enough to explain all dyskinesia of the elderly, because nerveous system
Complicated mechanism on system varying level can all produce influence to motion.Nervous system --- human brain weight at 90 years old
Mitigate 10~20% during compared with 20 years old.The reason for causing loss of weight essentially consists in the forfeiture of nerve cell.This funeral
Mistake has the specificity in region, and such as brain different zones Leukopenia degree is different.From birth to 10 years old god
Breed to most through cell, no longer divided, cell has started to lose after 20 years old.But full brain cell radix
Very big, part cell death will not cause the serious hindrance of function.Moreover people are solved to memory mechanism
It is also few, therefore caused by hypomnesia is not necessarily cell loss.Meninx thickeies after the elderly, and gyrus reduces,
Ditch, split wide and deep, ventricular cavity expands.Visible Nissl bodies are reduced in microstructure, and fat is brown
Matter is deposited.Functionally then see that MNCV slows down, recent memory goes down seriously than remote memory,
The physiologic sleep time shortens;The sensor capability such as sense of heat, tactile and seismesthesia all decline, and sense of taste threshold is raised,
Audiovisual susceptibility declines.Respond is generally reduced, particularly in the feelings for requiring to be made decision by selection
React more slow under condition.Cardiovascular system --- Aged Heart volume increases, there is presently no evidence table
What harmful effect is bright lipofuscin deposition have to myocardial function.In the visible pacemaker cells of the conducting system of heart
Quantity is reduced, and sinoatrial node increases with fibr tissue in internodal tract.In terms of artery, inner membrance also has different journeys
The thickening of degree, therefore can cause parteriole luminal stenosis.Coronary arterial tree began to after 30 years old to be occurred
Inner membrance is thickened, middle film fibrosis increasingly, some smooth muscles may necrosis, most prominent damped exponential model is
Elastomer flaggy becomes.Arteriovascular degeneration, peripheral vascular resistance increases so that angiosthenia is raised.Breathing
System --- the possible calcification of the elderly's costal cartilage in terms of form, bow-backed situation increased before causing thoracic cavity
Footpath expands afterwards turns into " emphysematous chest ".Visible breathing expands with respiratory bronchiole under microscope, makes surrounding
Alveolar is reduced.Digestive system --- generally the modal damped exponential model of digestive system is not notable,
The tooth that falls is good no relevant with protection to tooth, may not be aging feature.Visible stomach secretes sour thin under microscope
Born of the same parents are reduced with aging, and the cell number of hepatic tissue unit volume also declines, and Peyer's patches are at an early age
Most obvious excretory system people and rat kidney are all weightless in old age, and up to 20~30%, glomerulus number is reduced,
Normal glomerulus accounts for 95% at 40 years old, only remainings 63% at 90 years old, and proximal convoluted tubule length declines with volume,
Basilar memebrane thickeies with the age, and interstitial tissue increases in medullary substance.Functionally glomerular filtration speed declines.
The atrophy of internal system --- sexual gland is the most obvious damped exponential model of internal system.Such as women 45~50
Year or so ischomenia, estrogen secretion is remarkably decreased, and male gradually decreased from 50~90 years old androgen,
Sexual hypofunction.Reproduction corresponding to this and gonophore produce various atrophic changes, and such as ovary lymph is thin
The hormone that born of the same parents are formed, this results in immunity function decline.Molecular level --- device palace and the aging end of cell
Return relevant with the aging of molecular level, first for extracellular molecule, be filled in the extracellular knot of whole body
The basilar memebrane for forming tissue and epithelium has special damped exponential model.Connective tissue rich in collagen and
Elastin laminin.Cross-bond is produced between age growth collagen molecules.30~50 years old rapid for crosslinking
Increased period, the collagenous fibres water imbibition that increases with crosslinking declines, and loses toughness, tends to stiff,
It is unfavorable for the activity of tissue.Elastin laminin is the main component of elastomer, can also be handed in aging
Connection.Fibrous fracture, embrittlement, outward appearance yellow are deepened.Only know that it thickeies in aging as basilar memebrane, its
Main component is also collagen, secondary for glycoprotein and carbohydrate.But how these molecules change is led
Cause the thickening of film not clear.Additionally, also having blood, lymph certainly as extracellular material.These materials
Often in running status, and constantly update, it is difficult to make the index of aging.
In some specific embodiments of the invention, the aging is skin senescence.
In the present invention, the cosmetics refer to, to smear, spray or other similar approach, to impose on human body
Surface (such as epidermis, hair, nail, lip), plays cleaning, maintains, beautifies or eliminate bad gas
The product of taste effect, the product using position to that can have abirritation.
(1) classify by application target.Cleaning cosmetics:To clearing skin, the cosmetics of hair.
This kind of cosmetics such as cleansing cream, mildy wash, bath agent, hair-washing hair-care agent, shaving cream etc..Basic cosmetics:
Before cosmetic, the based process of opposite size hair.For example various face creams of this kind of cosmetics, honey, toner, face
Film, hair-cream, hair jelly etc. send out agent surely.Cosmetics:For face and the beautification articles for use of hair.It is this kind of
Cosmetics refer to kermes, lipstick, eye shadow, the articles for use such as hair dyeing and perm, hair style treatment, fixed.Curative effect is made up
Product:Daily chemical product between medicine and cosmetics.This kind of cosmetics such as freshener, deodorant, educate
Hair agent, hair remover, hair dye, pest repellant etc..
(2) classify by using position.Skin applies some make up:Refer to face and skin cosmetic.This kind ofization
For example various face creams of cosmetic, bath agent.Hair cosmetic:Finger sends out cosmetics special.This kind of cosmetics such as perfume
Ripple, mousse, hair sprays etc..Cosmetics:Beautifying face product is referred mainly to, also including nail head
The cosmetics of hair.Specific function cosmetics:Finger is added with the cosmetics of special role medicine.
(3) classify by formulation.Liquid make-up:Body lotion, shampoo, toner, perfume etc..Breast
Liquid:Sweet class, milk.Cream kind:Profit face cream, vanishing cream, hair cream.Powder class:Face powder, talcum powder.
It is block:Muffin, cosmetic container.It is bar-shaped:Lipstick, pomade.
(4) age-based classification.Baby applies some make up:Infant skin is tender and lovely, vulnerable.During preparation
Low irritant raw material, essence should be selected will also select the excellent product of low stimulation.Teenager applies some make up:It is juvenile
Skin is in the puberty, and skin condition is unstable, and acne easily long.Adjustment sebum secretion is can select to make
Raw material, prepares weak oil-based cosmetic preparation.Men's cosmetics:The many rooms of male should be selected in lipid skin
It is suitable to the raw material of lipid skin.Liquid is the special cosmetics of man after shaving cream, palpus.
(5) seven classes can be divided into by production process combination product feature.Emulsion class:Refer to various cream honey.
Powder class:Various face powders, talcum powder.Beauty class:Refer to lipstick, eye shadow, mascara, nail polish etc..It is fragrant
Water class:Perfume, cologne, floral water.Shampoo class:Refer to shampoo, body lotion, hair conditioner.Hairdressing class:
Refer to hair dyeing, hair-waving, determine hair care product.Curative effect class:Add the cosmetics of medicine.
In some specific embodiments of the invention, the formulation of the cosmetics is aqua, mellite, milk
Agent, paste, creme, pulvis, bulk, it is bar-shaped in one or more.
In some specific embodiments of the invention, the concentration of the peptide is 0.01-100 μM.
In other specific embodiments of the invention, the effective dose of described peptide is 0.1-10 μM.
In other specific embodiments of the invention, the effective dose of described peptide is 0.01,0.1,
10 or 100 μM.
This experiment uses molecular database.The database mainly includes Chinese herbal medicine monomer molecule, small molecule
Compound, the compound structure extracted from natural products and the virtual compound produced with computer approach,
In Computer-Aided Drug Design, it is mainly used in based on molecular property, pharmacophoric group and molecular docking
Database search.On the one hand it can provide natural products three-dimensional structure information, on the other hand, database
The important informations such as plant origin, traditional function, association area scientific research progress can also be provided.This
Mesh passes through molecular docking technology, it is intended to search out the natural product for having specific bond with EGF-R ELISA
Thing, so as to develop the natural products medicine of efficient, high selectivity, while natural products can also be studied
The mechanism of action in vivo.With the accumulation of the natural products data in Chinese herbal medicine, this project experimental result
With further research and development and value, be conducive to illustrating and probing into for small molecule mechanism of action.
During the present invention by tripeptides Arg-Arg-Tyr by acting on HSF, to application on human skin into
Fibrocyte carries out CCK-8 proliferation experiments, Edu methods detection cell proliferation experiment, flow cytomery
Cell cycle tests.It is experimentally confirmed that tripeptides Arg-Arg-Tyr can effectively facilitate HSF's increasing
Grow, increase S+G2M phase proportions, it is used for skin senescence prevention or treatment determined curative effect, side effect
It is small, therefore have important practical significance.
Brief description of the drawings
In order to illustrate more clearly about the embodiment of the present invention or technical scheme of the prior art, below will be to reality
The accompanying drawing to be used needed for example or description of the prior art is applied to be briefly described.
Fig. 1 shows EGFR molecular models:Shown in front view such as Fig. 1 (A), top view such as Fig. 1 (B)
It is shown;
Fig. 2 shows influences of the Arg-Arg-Tyr to proliferation of human dermal fibroblasts;
Fig. 3 shows the influence that Arg-Arg-Tyr breeds to HSF;Wherein, Fig. 3 (A) shows fluorescence microscope
Take pictures figure;Fig. 3 (B) shows fluorescence picture software analysis figure;
Fig. 4 shows cell cycle analysis figure;
Fig. 5 shows cell cycle statistic histogram;
Fig. 6 shows the visual results of control group in embodiment 3;
Fig. 7 shows the visual results of small peptide group in embodiment 3;
Control group HE dyes × 100 results during Fig. 8 shows embodiment 3;
Small peptide group HE dyes × 100 results during Fig. 9 shows embodiment 3.
Specific embodiment
The invention discloses a kind of peptide and its application, those skilled in the art can use for reference present disclosure, fit
When modified technique parameter is realized.In particular, all similar replacements and change are to this area
It is it will be apparent that they are considered as being included in the present invention for technical staff.The method of the present invention and
Using being described by preferred embodiment, related personnel substantially can not depart from present invention,
Realized to method described herein and using being modified or suitably changing with combining in spirit and scope
With application the technology of the present invention.
In order to overcome prior art deficiency problem, it is an object of the invention to provide a kind of tripeptides ---
The application of Arg-Arg-Tyr, it has significant curative effect in the cosmetics for preventing and/or treating skin senescence.
In order to solve the above technical problems, the technical solution adopted by the present invention is:A kind of tripeptides ---
Applications of the Arg-Arg-Tyr in preparing for preventing and/or treating skin senescence cosmetics.
Further, described tripeptides --- Arg-Arg-Tyr is used to prevent and delaying skin protective agent.
The concentration of the tripeptides Arg-Arg-Tyr is 0.01-100 μM.
The present invention has following beneficial effect:SF can be effectively facilitated to breed, anti aging effect,
Simultaneously also have it is easy to use, raw material sources extensively, it is cheap, reduce cosmetics toxicity, safety
Performance is good.Specifically, during the present invention by tripeptides Arg-Arg-Tyr by acting on HSF,
CCK-8 proliferation experiments, Edu methods detection cell proliferation experiment, streaming are carried out to HSF
Cell instrument detection cell cycle experiment.It is experimentally confirmed that tripeptides Arg-Arg-Tyr can effectively facilitate application on human skin into
Fibrocyte proliferation, increases S+G2M phase proportions, and it is used for skin senescence prevention or treatment curative effect is true
Cut, Small side effects, therefore have important practical significance.
Raw materials used and reagent can be bought by market in a kind of peptide of present invention offer and its application.
With reference to embodiment, the present invention is expanded on further:
Embodiment 1:Computer molecular simulation screening function small peptide is tested
1.1 experiment materials
It is equipped with the supercomputer of 192AMD Opteron processor groups
1.2 experimental techniques:
The principle of high flux computer molecular simulation triage techniques is as follows:(1) the preliminary sieve of pharmacophore and target spot
Choosing.Existing Chinese medicinal herb monomer database is utilized, analysis comprehensively is carried out to acceptors such as protein.
The interaction of simulation Chinese herbal medicine monomer molecule and target recipient protein molecular, and obtain this several material
With reference to score and action site.(2) molecular docking.It is small by continuing to optimize using semi-flexible docking calculation
The position (orientation) of molecular compound and the dihedral angle (conformation) of intramolecule flexible bond, find small point
The best conformation that sub- compound is acted on target macromolecule, it is allowed to which the conformation of small molecule changes, then
Molecule in storehouse is docked with target molecule one by one, calculations incorporated free energy.Using Conjugated free energy as
The foundation of docking result is evaluated, according to this score rank, the optimal molecule combined with target molecule is found out.(3) divide
Subdynamics is simulated.Molecular dynamics is carried out to receptor-ligand complex in the case of virtual with computer
Simulation, simulates the compound most stable of form in its natural state, and make data analysis.Can be very
Good simulated in vivo environment, by fine calculating, can accurately represent the journey of acceptor and ligand binding
Degree.Fine screening process uses the high-performance computer system of the series of dawn 5000, using multi-core parallel concurrent
Calculation, greatly improves the progress of experiment.
Molecular docking is the main experimental methods of this phase experiments.Given birth to by studying smaller ligand and acceptor
The interaction of thing macromolecular, the binding pattern and affinity of the predictable compound of computer, are current medicines
One of most important methods in field such as thing design.Molecular docking is smaller ligand and large biological molecule acceptor
The process being mutually distinguishable by geometric match and energy match.The mistake of drug effect reaction is produced in drug molecule
Cheng Zhong, drug molecule be combined with each other with target, first has to two molecules and is substantial access to, and takes and suitably takes
To, both is mutually agreed with necessary position, interact, continue and adjusted by appropriate conformation
It is whole, obtain a compound conformation for stabilization.Two molecules are correct in determining compound by molecular docking
Relative position and orientation, research two conformations of molecule, the particularly conformation of substrate formed compound
During change, be to determine mechanism of drug action, design new drug basis.The following is main several points
Sub- docking calculation, refers to table 1:
Several main molecular docking methods of table 1
It is of the invention mainly to realize that molecular docking is calculated using Autodock.
Molecular docking is calculated:Ligand molecular is placed on the position in receptor active site, it is then mutual according to geometry
The quality of the principle Real-Time Evaluation parts such as benefit, chemical environment complementation, energy complement and acceptor interaction,
And find optimal binding pattern between two molecules.
Evaluation method:It is estimated by scoring functions.The arithmetic of each docking is in computer molecular sieve
Select and can all carry out free energy function marking in platform, the process need to balance following two factors:It is ageing and
Accuracy.This evaluation at present mainly includes following three part:1. the method for the regression parameter of experience is based on,
Contribution of the various physical parameters to Conjugated free energy, such as FlexX programs are fitted with the method for multiple regression
Number, hydrogen bond, the ionic bond of middle use part rotation key, the pi accumulation of hydrophobic and aromatic rings are acted on, with
And hydrophilic interaction.This method quickly can directly estimate Conjugated free energy;2. the side of molecular force field is based on
Method, the method only considers contribution of the heat content to energy, and the influence of entropy is not considered, generally, uses
The non-binding effect in the standard field of force can serve as scoring functions, such as DOCK such as vacuum static electricity and model ylid bloom action
Using the energy function of AMBER in program:
3. Knowledge based engineering scoring functions.It is initially applied to protein structure prediction, scoring functions statistical mechanics
Method obtain the composite structure of protein-ligand, Conjugated free energy function is flat for intermolecular distance
Can plus and to calculate.
1.3 experimental procedures:
1.3.1 clear and definite simulated object:
The simulated object of this term computer molecular simulation experiment is part to be calculated and EGFR albumen knots
Structure (Fig. 1), wherein, Fig. 1 (A) is front view, and Fig. 1 (B) is top view.All EGFR albumen
Structure comes from Protein Data Bank, and predominantly resolution isEGFR extracellular domain crystal structures
(PDB is numbered:1NQL), and resolution isThe allosteric for combining EGF after EGFR
(PDB is numbered extracellular domain crystal structure:1IVO).
The preparation of protein structure is the essential step of virtual screening.The structure of the protein target of virtual screening
Can be from PDB storehouses (http://www.rcsb.org/pdb/index.htmL) in directly download and use;Can also lead to
Cross and family in the sequence of homologous protein, structural information compare, Blast search and obtain.Removal acceptor molecule
In all hydrones and metal ion.The description of binding site is followed by, suitable ligand binding is selected
Pocket.This experiment is the accuracy of guarantee experimental result, and we such as combine according to biological function, are mutated
Experiment information, manually selects binding site.
1.3.2 modeling scheme is formulated:
First by the PDB files that software SYBYL1.1 modifications are obtained, redundancy molecule and unrelated is deleted
Group, to obtain pure protein structures;
Secondly software Autodock4.0 installation space coordinates are used, by Lamarckian genetic algorithm
(Lamarckian genetic algorithm), it is stipulated that the binding site of drug molecule, selected avtive spot
It is the binding site of part (referred to herein as EGF).Now initial setting up is finished.
1.3.3 molecular simulation is calculated:
Including docking and giving a mark, this step is the core procedure of virtual screening.Docking operation is that each is small
Molecule is put into the ligand binding site of receptor protein, optimizes part conformation and position, is allowed to have most with acceptor
Good combination;The marking of best combination conformation is given, all compounds are sorted according to marking, Ran Houcong
Choose marking highest small molecule in compound library.
Using the AutoGrid modules in Autodock, the Conjugated free energy between part and acceptor is calculated.
It is now preliminary screening, it is already possible to obtain the affine information of a part of molecule and EGFR;
Simulating external member using AMBER 11 carries out the simulation and data analysis of molecular dynamics.In EGFR
Simulation in use the field of force be AMBER ff03, this field of force to the alpha-helix and β of secondary protein structure-
The stress force distribution of folding is more balanced, therefore more suitable for the simulation of EGFR.Simulated environment is used
TIP3P water box, i.e. water environment, because main component is water in human body, therefore test mesh according to this project
, it is rational as the experiment condition of molecular simulation to choose water environment, can fully simulate the water in human body
Environmental effect;
The geometry for carrying out ligand molecular using Gaussian03 programs is optimized, and is obtained most stable of quiet
Energy of position;
Use remaining force field parameter of AMBER GAFF procedure stipulation parts;
The force field parameter that part is lacked is set using the antechamber external members of the softwares of AMBER 11.
, using the AutoGrid modules in Autodock, the combination between calculating part and acceptor is certainly for this phase experiments
By energy.
1.3.4 the post processing of compound is hit:
The post processing for hitting compound (is absorbed by calculating the quasi-medicated property matter ADME/T of molecule
Absorption, in vivo organ distribution distribution, metabolism metabolism, excretion excretion and poison
Property toxicity) property estimation, exclude those molecules without quasi-medicated property matter.
Because EGFR is a relatively large molecular system, need to expend sizable in molecular simulation
Amount of calculation, therefore we employ the simulated time of 5ns in medicine preliminary screening.Length is away from electrostatic force
Calculated using Particle-Mesh Ewald methods, in calculating process, we with the addition of sodium ion, in
The negative electrical charge produced with EGFR.
Finally, the Conjugated free energy of EGFR and part can be calculated, such that it is able to ligand activation
The ability of EGFR makes a computer evaluation.Four steps are processed more than, and most of molecule is from compound
Rejected in storehouse, form a compound library for size reasonable, the only compound to these suitable patent medicine or purchase
Buy or synthesize or be isolated, actual biological test is then carried out again.
1.4 experimental results and analysis
Forgive having set up the albumen database of 8000 kinds of small peptide three-dimensional structures, by the sieve to the small peptide storehouse
Choosing, because the spatial conformation of short peptide molecules is complicated, in actual molecular simulation screening, score absolute value
It is more than 8 points " there is the target molecule for preferably combining effect ".Therefore, this experiment calculates knot according to final
Really, obtain that there is the small peptide for preferably combining effect with EGFR, as a result as shown in formula I:
Arg-Arg-Tyr (Arg-Arg-tyrosine), simulates score twice:-9.5;-9.7
Embodiment 2:Influences of the Arg-Arg-Tyr to proliferation of human dermal fibroblasts
1 material
1.1 cell lines
HSF's strain (HSF), is purchased from Fudan University's IBS cell resource centers.
1.2 biochemical reagents
Pen .- Strep solution (100 ×), pancreatin cell dissociation buffer (containing phenol red), Phosphate-Buffered
Saline (NaCl containing 135mM, 4.7mM KCl, 10mM Na2HPO4, 2mM NaH2PO4, pH
It is worth 7.4), to be green skies Bioisystech Co., Ltd product;DMEM high glucose mediums, cell freeze
Liquid storage, U.S.'s Gibco Products;Australia top grade hyclone, Gemini companies of the U.S.;
TritonX-100, bovine serum albumin(BSA) (BSA) are the big bio tech ltd of Guangzhou Ztel;Sodium chloride,
Absolute ethyl alcohol, paraformaldehyde, dimethyl sulfoxide (DMSO) (DMSO), are Guangzhou chemical reagent Co., Ltd product,
Analysis is pure.
1.3 biochemical reagents boxes
CCK-8 kits, Japanese DOJINDO companies;The propagation detection examination of key Fluor488-EdU methods cell
Agent box, cell cycle detection kit, are Nanjing Keygen Biotech's Products.
1.4 conventional biochemistry consumptive materials
6 holes, 24 holes, 96 porocyte culture plates, 25cm2Tissue Culture Flask, 0.22 μm of needle-based are sterile filtered
Device, 15mL, 50mL sterile centrifugation tube is Jie Te biotech firms (JET) product;Cryopreservation tube, Sigma
Products;Fluidic cell pipe, U.S. company BD product.
1.5 key instruments
EPICS XL-MCL type flow cytometers, U.S.'s Beckman Co μ Lter Products;Carbon dioxide
Incubator, Biohazard Safety Equipment, are skill and think (ESCO) Science and Technology Ltd. high product;Inverted microscope,
Japanese OLYMPUS Products;TW12 thermostat water baths, German J μ Labo Products;AL
104-IC electronic analytical balances, Switzerland's Mettler Products;The type ELIASAs of Model 680, the U.S.
Bio-RAD Products;5810R table-type high-speed refrigerated centrifuges, German Eppendorf Products;
Micropipettor, German Eppendorf companies;The intelligent inverted fluorescence microscopes of DMI4000B, Germany
Leica Products;Cell counting count board, Shanghai refinement biochemical instrument company;Cell cryopreservation program temperature reduction box,
U.S.'s Nalgene Products;Liquid nitrogen container, U.S.'s Thermo Products;80 DEG C of low temperature refrigerators of ﹣,
U.S.'s Thermo Products;20 DEG C of low temperature refrigerators of ﹣, Qingdao Haier Products.
1.6 medicines
EGF, unlimited pole (China) Co., Ltd;Arg-Arg-Tyr (RRY) purity 99.33%, Shanghai is strong
Credit bio tech ltd's product.
The preparation of 1.7 cell culture common experimental reagents
1.7.1 integral asepsis cell culture medium
DMEM high glucose mediums 90mL, hyclone 10mL are measured under aseptic condition, is mixed, plus
Enter mycillin solution 1mL, packing after 0.22 μm of membrane filtration is degerming, be stored in 4 DEG C it is standby.
1.7.2EGF the preparation of working solution
(1) EGF is 1mg/ pipes, adds 10mL complete mediums, and concussion is mixed, and is made into 10mg/mL's
Mother liquor, packing, 20 DEG C of ﹣ keeps in dark place;
(2) dilution of 10 μ L EGF mother liquors is taken before testing, finally configures other concentration respectively 100ng/mL's
EGF working solutions.
1.7.3 small peptide Arg-Arg-Tyr working solutions are prepared
(1) small peptide Arg-Arg-Tyr is 10mg/ pipes, adds 20.125mL complete mediums, and concussion is mixed,
1000 μM of mother liquor is made into, is dispensed, 20 DEG C of ﹣ keeps in dark place;
(2) mother liquor dilution is taken before testing, other concentration is finally configured and is respectively 100,10,1,0.1,0.01 μM
RRY working solutions.
1.7.4 4% paraformaldehyde solution
Weigh in the poly formic acid addition 900mI PBS of 40g, be sealed in wide-mouth bottle after being sufficiently stirred for, be placed in
60 DEG C of incubators heat dissolution, add PBS to be settled to 1000mL until completely dissolved, and 4 DEG C save backup.
1.7.5 3%BAS solution
Weigh in 3g BAS addition 100mL distilled waters, fully 4 DEG C of short-term preservations are standby after dissolving.
1.7.6 0.5%TritonX-100
Measure in 50 μ L TritonX-100 additions 9mLPBS, vibration is mixed, and is settled to 10mL, make it dense eventually
Spend is 0.5%.
2 experimental techniques
2.1 cell culture processes
2.1.1 culture environment
HSF is incubated in the DMEM nutrient solutions containing 10% hyclone (pH7.2~
7.4), in 5%CO2, routine passage culture in 37 DEG C of saturated humidity incubator.
2.1.2 cell recovery
1) beaker of 37 DEG C of water-baths or 1000mL, built-in 2/3 glass 37 DEG C of warm water are prepared.
2) cryopreservation tube is taken out from liquid nitrogen, is immediately placed in warm water and is constantly stirred.Make to freeze thing in cryopreservation tube
Melted within 1 minute.
3) with 75% alcohol wipe sterilize after, on clean bench open lid, with suction pipe suction out cell suspension, load from
In heart pipe, then 10mL nutrient solutions are added, piping and druming makes cell suspend.
4) 1000rpm is centrifuged 10 minutes, abandoning supernatant.
5) precipitation plus 10mL nutrient solutions, piping and druming is uniform, then is centrifuged 10 minutes, abandons supernatant.
6) plus after appropriate culture medium cell is transferred in blake bottle, culture, second day in 37 DEG C of cell culture incubators
Observation growing state.
2.1.3 the passage of cell
1) passed on when cell is paved with bottom of bottle.First original culture medium is outwelled, PBS is subsequently adding and is washed 3
It is secondary.
2) to the trypsase that 1mL 0.25% is added in bottle, blake bottle is shaken gently for, flows through digestive juice all
Cell surface, then sop up or outwell after digestive juice again plus 1mL it is new tryptic digestive juice, gently
Most of digestive juice is outwelled after shake again, is only stayed and is digested a little, basis of microscopic observation.
3) separated when discovery cell is connected to each other, when kytoplasm retraction is rounded but still end completely falls off, after discarding pancreatin
3mL DMEM culture mediums are added immediately, terminate digestion.
4) micropipettor is used, nutrient solution in bottle blowing is drawn, bottle wall cell dispersion is blown and beaten repeatedly.
5) after cell is uniformly dispersed, 1:3 passages.
2.1.4 cell freezes:
1) HSF of 80% or so degrees of fusion, method digestion as described above, centrifugation, abandoning supernatant will be grown to;
2) cells frozen storing liquid (4 DEG C of precoolings), piping and druming is added to be transferred to 2mL cell cryopreservation tubes after mixing in cell precipitation;
3) cryopreservation tube is put into cell cryopreservation program temperature reduction box, is placed in 80 DEG C of refrigerators of ﹣, and cryopreservation tube is taken out after 24 hours,
Fast transfer to liquid nitrogen container is preserved.
2.2CCK-8 proliferation experiments
2.2.1 cell recovery and passage
Method is with 2.1.2 and 2.1.3.
2.2.2 cell suspension is prepared
Take the logarithm the cell in growth period, abandon old nutrient solution, with PBS washed cells 3~4 times, then with 0.25%
Trypsin Induced, abandons trypsase and adds new culture medium and terminate digestion after digestion, piping and druming cell make its from
Completely fallen off in bottle wall.Centrifuge tube centrifugation 1000r/min is conducted into, 5min is centrifuged.After centrifugation, abandon
Fall supernatant, re-replace culture medium.
2.2.3 cell count
Tally and special cover glass are cleaned with 95% alcohol, is then dried at room temperature or is wiped dry with silk.
A little cell suspension for preparing is taken, one end of cover glass is added dropwise the cell suspension of pettiness amount on tally,
To prevent suspension from overflowing cover glass or overflowing into the glass guide channel of both sides during dropwise addition, sample-adding amount also should not it is very few or
Band bubble.Observed under inverted microscope, under 10 × object lens, in the block plaid of four, count plate periphery
Cell number.Result of calculation is substituted into following formula, cell density is drawn
Cell number/milliliter stoste=(4 cell number/4 of block plaid) × 104
2.2.4 cell inoculation
The concentration results that reference cell tally is drawn, by 4X103/ hole density, 200 μ L/ holes are inoculated in
96 orifice plates.The μ L of PBS liquid 200 are drawn with sample loading gun be injected separately into 96 orifice plate rims surroundings (resistance edge
Effect), after the completion of bed board, close the lid, indicate the date.It is put into 5%CO2, train in 37 DEG C of incubator
4~6h is supported, until cell adherent dosing completely.
2.2.5 pharmaceutical intervention is carried out
When cell is completely adherent, nutrient solution in each hole is suctioned out.If positive controls (EGF, 100ng/mL)
﹑ negative control groups (only adding single cell suspension to be not added with any medicine) and experimental group, experimental group is divided into dense
Spend for 100,10,1,0.1,0.01 μM of every group of each concentration sets 5 multiple holes, each hole final volume is 200 μ L,
Again 96 orifice plates are continued to be placed in 5%CO2Cultivated in the saturated humidity incubator of 37 DEG C of ﹑, trained after dosing
Foster 72h is measured.
2.2.6 colour developing and ELIASA detection:
Original fluid is removed under the 4h before cell culture terminates, aseptic condition, is added per hole
20 μ L10%CCK-8 solution, 37 DEG C of incubation 4h.Orifice plate is taken out, at ELIASA detection 450nm wavelength
Light absorption value.Data output, record analysis.
2.3Edu methods detection cell propagation
2.3.1 cell recovery and passage
Method is with 2.1.2 and 2.1.3.
2.3.2 cell inoculation
Take the logarithm the HSF cells in growth period, after being rinsed with PBS, plus the digestion of pancreatin cell dissociation buffer, from
The heart is collected, and abandons supernatant, adds fresh culture resuspended, is inoculated in containing thin according to the concentration in 10000/hole
In 24 well culture plates of born of the same parents' creep plate, 37 DEG C, 5%CO are placed in212h is cultivated in incubator.
2.3.3 dosing and incubation
After cell growth is adherent, nutrient solution is suctioned out, add various concentrations, final concentration is respectively 100,
10th, negative control and Positive control wells are set up simultaneously and 3 multiple holes are respectively set up for 1,0.1,0.01 μM.Plus
Continue culture 72h after medicine under the conditions of.
2.4.4 using the key Fluor488-EdU methods cell proliferation detecting kit detection of Nanjing Kai Ji companies production
The influence of small peptide cell proliferation, to specifications step operation:
2.4.4.1EdU mark:
1) by cell culture complete medium and EdU solution according to 2000:The appropriate 50 μM of EdU dilutions of 1 proportions
Liquid.
2) 50 μM of the μ L/ holes of EdU dilutions 200,37 DEG C, 5%CO are added2Incubator is incubated 4h, abandons culture
Base.
3) PBS cell, 5min/ times × 2 times, abandons PBS.
2.4.4.2 cell is fixed and promotees to ooze:
1) cell fixer (i.e. containing the PBS of 4% paraformaldehyde) 100 μ L/ holes are added, 30min is incubated at room temperature, is abandoned
Cell fixer.
2) the PBS100 μ L/ holes containing 3%BSA, cleaning, 5min/ times × 2 times are added.
3) bleeding agent (PBS of 0.5%TritonX-100) 200 μ L/ holes are added, room temperature decolorization swinging table is incubated 20min,
Abandon bleeding agent.PBS 1 time, 5min.
2.4.4.3EdU detect:
1) 1 × Click-iTEdU reaction buffers are prepared:Transfer 1 × Click-iTEdU reaction buffer reagent bottles
In all of solution 4mL to 36mL deionized water in.
2) prepare a 10 × Click-iTEdU reaction additive liquid storages:Plus 1mL deionized waters to 10 ×
In Click-iTEdU reaction additive liquid storage test tubes, mix to whole dissolvings.
3) 1 × Click-iTEdU buffer solutions additive (being shown in Table lattice 2) are prepared:10 × liquid storage is diluted with deionized water
To 1 ×, solution answers Fresh, and the same day is finished.
4) Click-iT reactant mixtures are prepared according to table 2.
The Click-iT reactant mixtures of table 2:
5) removal promotees sepage, is washed 2 times with the cleaning solution of the PBS of the 3%BSA of every hole 1mL, and removal is washed
Wash liquid.
6) add 0.5mL Click-iT reactant mixtures to every creep plate, briefly rock culture plate to ensure reaction
Mixture can be with uniform fold creep plate.
7) room temperature lucifuge is incubated 30min.
8) reactant mixture is removed, is washed 2 times with 1mL3%BSAin PBS per hole, remove cleaning solution.
2.4.4.4DNA dye:
1) every hole is washed 1 time with 1mLPBS, removes cleaning solution.
2) with PBS dilution Hoechst33342 liquid storages 1:2000 to 1 × Hoechst33342 solution, final concentration
It is 5 μ g/mL.
3) 1mL1 × Hoechst33342 solution is added per hole, room temperature lucifuge is incubated 30min.Remove Hoechst33342
Solution.
4) the every hole of 1mLPBS washings 2 times, removes cleaning solution.Seen under fluorescence microscope blueness and green fluorescence
Examine, every cell climbing sheet randomly selects 5 visuals field and taken pictures, and image is entered using Image J softwares
Row counts proliferating cell nuclear and total cell check figure mesh.
5) new proliferative cell excites lower nucleus to send the prominent light of green in blue light, all of cell (including new propagation and
The cell of non-multiple fission) nucleus sends blue prominent light under burst of ultraviolel.By red proliferating cell nuclear
Number and blue total cell nuclear phase ratio, be calculated EdU positive cell percentages, can detect cell
Proliferative conditions.
2.4 flow cytomery cell cycles
2.4.1 cell recovery and passage
Method is with 2.1.2 and 2.1.3.
2.4.2 cell inoculation
Take the logarithm the HSF cells in growth period, after being rinsed with PBS, plus the digestion of pancreatin cell dissociation buffer, from
The heart is collected, and abandons supernatant, adds fresh culture resuspended, and adjustment cell concentration is 1.0x105/ mL, 2mL/
Hole is inoculated in 6 orifice plates, is placed in 37 DEG C, 5%CO212h is cultivated in incubator, treats that cell is completely adherent
Afterwards, serum-free medium domestication 24h, makes cell cycle synchronization.
2.4.3 dosing and incubation
Nutrient solution is suctioned out, various concentrations are added, final concentration is respectively 100,10,1,0.1,0.01 μM
Negative control and Positive control wells are set up simultaneously and respectively set up 4 multiple holes.Continue training after dosing under the conditions of
Support 72h.
2.4.4 the shadow of small peptide cell cycle is detected using the cell cycle detection kit of Nanjing Kai Ji companies production
Ring, to specifications step operation:
1) once (2000rpm, 5min is centrifuged) and collects and adjust cell concentration with PBS washed cells and be
1x106/ mL, takes 1mL single cell suspensions;
2) after the single cell suspension centrifugation for preparing, supernatant is removed, it is 70% cold second that volume fraction is added in cell
The μ L of alcohol 500 are fixed (2 hours to overnight), 4 DEG C of preservations, and fixer is washed away with PBS before dyeing;
3) 100 μ L RNase A37 DEG C water-baths 30min are added;
4) add 400 μ L PI dyeing to mix, 4 DEG C of lucifuge 30min;
5) machine testing on, red fluorescence at record excitation wavelength 488nm;
6) experiment is repeated 3 times;
7) using the software analysis datas of ModFit LT 4.1.Result is with proliferation index (proliferous index, PI)
That is S and G2M phase cell percentages represent, computing formula:PI=(S+G2/M)/(G0/G1+S+
G2/ M), the cell proportion size in the active proliferation phase is shown with this.Experiment is repeated 4 times.
2.5 statistical procedures
All experimental datas are added and subtracted standard deviation (x ± s) and are represented with mean, multigroup as a result with the software processings of SPSS 11.0
Between compare and use one-way analysis of variance, compare two-by-two using Dunnett-t inspections.P < 0.05 are have statistics
Learn meaning.
3 experimental results
3.1CCK-8 methods detect influences of the Arg-Arg-Tyr to HSF multiplication capacities
It is small with (0.01,0.1,1,10,100 μM) treatment HSF cells 72 of various concentrations Arg-Arg-Tyr
When, cck-8 detect HSF cells propagation, compare with negative control group, Arg-Arg-Tyr 0.01,0.1,
1st, 10,100 μM for the treatment of groups and negative control group comparing difference significantly (p<0.05).Wherein 1 μM group with
0.01st, 0.1,10,100 μM of groups are compared, P<0.05, statistically significant, i.e. Arg-Arg-Tyr concentration
For 1 μM when, the quantity of born of the same parents is most.But it is (positive right for 1 μM of Arg-Arg-Tyr and 100ng EGF
According to group) difference between the effects of two groups are not statistically significant.Specific data are shown in Table 3, Fig. 2.
To sum up, various concentrations Arg-Arg-Tyr (0.01,0.1,1,10,100 μM) can cause HSF
Propagation.We select 0.1,1,10 μM of Arg-Arg-Tyr to process cell in follow-up experiment.
The Arg-Arg-Tyr of table 3 intervenes lower each group cell OD values (x ± s)
Note:*P<0.05, pharmaceutical intervention group is compared with negative control group;#P<0.05,1 μM of Arg-Arg-Tyr group
Compared with other concentration Arg-Arg-Tyr groups.
3.2EdU methods detect influences of the Arg-Arg-Tyr to HSF multiplication capacities
Cell 72h is processed with 0.1,1 and 10 μM of Arg-Arg-Tyr and 100ng EGF respectively, is used
EdU detects the proliferation number of cell.As shown in Fig. 3 (A) and Fig. 3 (B):Blueness figure (Hoechst)
The all staining cell cores under the fluorescence microscope visual field are represented, green figure (EdU) is represented newly breeds in the visual field
Nucleus, Merge is both fusion figures.Compared with Control groups, increasing occurs in 1 μM of cell of group
Grow (P<0.05).Result shows that 1 μM of Arg-Arg-Tyr can cause cell to be bred.But for 1 μM
The difference between the effects of two groups of Arg-Arg-Tyr and 100ngEGF are not statistically significant.
Influences of the 3.3RRY to the HSF cell cycles
As shown in Figure 4,5 apply stimulate 72h after, experimental group (1 μM of Arg-Arg-Tyr) with compare
Group is compared, and DNA pre-synthesis phases (G1) cell percentage has been reduced, and reflects cell
Substantially (P < 0.05) is raised the PI proliferation indexs [i.e. (S+G2M)] of proliferation activity.Result shows 1 μM
Arg-Arg-Tyr can cause cell breed (P<0.05).But for 1 μM of Arg-Arg-Tyr and
The difference between the effects of two groups of 100ngEGF are not statistically significant.
The animal experiment of embodiment 3
1 materials and methods
1.1 experimental animals:SD mouse 18, female, the scholar 0.6g of body weight 18.0, purchased from Zhongshan University's zoopery
Center.
1.2 experiment reagents:Arg-Arg-Tyr (RRY) purity 99.33%, Shanghai is shone by force the limited public affairs of biotechnology
Department's synthesis;1 μM of solution is formulated as with distilled water.
1.3 instruments:
Leica paraffin slicing machines, German Leica Products;Shandon Paraffin Section Flotation Bath
Stand piece machine, U.S.'s Thermo Fisher Scientific Products;The upright micro-imaging systems of DM 2500B
System, German Leica Products.
1.4 experiment packets and treatment:
Using random number method, 12 SD mouse are randomly divided into 2 groups, every group 6:Blank control group:Not
Give any treatment;1 μM of Arg-Arg-Tyr solution small peptide group.Above-mentioned each group starts the previous day back of the body in experiment
Portion's shaving (through in whole experiment process), scope is 4 × 4cm2Size, applies in shaving area skin and uses
Above-mentioned relative medicine, 1 times/day, continuous 1 month.
1.5 skin surfaces are visually observed
The color and luster of mouse back skin is visually observed, smooth degree and wrinkle situation etc. judge that animal skin changes
Situation, as the observation index of macroscopical figure and features.
1.6 Histomorphologicals
Concrete operations are as follows:
1.6.1. collection of specimens
30d is tested, all chloraldurates of animal intraperitoneal injection 10% are anaesthetized, cervical dislocation puts to death animal.
Quick clip back of the body back about 4 × 4cm2The depilation skin of size, carefully removes subcutaneous superabundant fats, takes part
Skin sample, carefully shakeouts, and 10% formaldehyde fixes more than 48 hours, and work done in the manner of a certain author is carried out for Skin slice
Histomorphological.
1.6.2. FFPE
The skin histology that taking-up is fixed, is rinsed overnight with flowing water, and next day carries out the FFPE of following steps:70%
Ethanol 1h → 80% ethanol 1h → 90% ethanol 1h → 95% ethanol (I) 1h → 95% ethanol (II) 1
H → 100% ethanol (I) 1h → 100% ethanol (II) 1h → n-butanol 1h → dimethylbenzene 30min → molten wax
(I) 1.5h → molten wax (II) 2h → embedding.
1.6.3 microsection manufacture
Conventional dermal tissue paraffin section, thickness 6nm, will make section Yu room temperatures Xia Liao it is dry overnight, then
4 refrigerator sealing preserves are put into, it is standby.
1.6.4 skin histology HE dyeing
1) section dewaxing and rehydration
The ethanol 2 of dimethylbenzene (I) 2min → dimethylbenzene (II) 10min → 100% ethanol 2min → 95%
Min → 80% ethanol 2min → 75% ethanol 2min → originally wash 2min.
2) dye:Haematine dye 3min → running water embathes and returns blue 3min → aquae destillata and embathe 3min;
3) it is dehydrated transparent:70% ethanol 2min → 80% ethanol 2min → 90% ethanol 2min → 1% eosin stains
3s → 95% ethanol 2min → 100% ethanol (I) 2min → 100% ethanol (II) 2min → dimethylbenzene (I) 6
Min → dimethylbenzene (II) 6min → neutral gum mounting, airing.
4) microscopy observation.
The depth for often examining under a microscope dyeing is taken in HE dyeing, as a result should be cell so as to regulation and control in time
Core is dyed to blueness, and kernel is clearly demarcated, and cytoplasm is dyed red, blue nucleus and red by Yihong
Endochylema is with distinct contrast.
2 results
2.1 each group mouse back skin gross morphologies are observed
Blank control group mouse skin is ruddy, smooth, without obvious wrinkle, full of elasticity;Experimental group
(1 μM of Arg-Arg-Tyr solution small peptides group) ruddy gloss of skin, thickness is moderate, with good skin
Elasticity, and compared with blank control group mouse dorsal part epidermis without pachyderma, furfur, color burn etc. no
Good reaction.(see Fig. 6~7).
2.2 each group mouse back skin tissue morphologies are observed
HE results show that each Rotating fields of blank control group mouse skin are complete, and subcutaneous hair follicle, sebaceous glands are satisfied
Full, epidermis rule, epidermis is clear with corium boundary line, and just, even dyeing is fine and close, collagen for skin corium thickness
Fiber bundle-like is arranged, neatly fine and close;Experimental group (1 μM of Arg-Arg-Tyr solution small peptides group) mouse skin
Skin epidermis structural integrity, cell layering is clear, and thickness is normal, cell component and moderate number, corium
The visible wavy fibr tissue of layer, aligned orderly is evenly distributed, reasonable organization, and and blank control group
Compared to indifference.(see Fig. 8~9).
3 conclusions
The present invention is visually observed by integrated use, HE colouring methods, in terms of tissue morphology biology
Experiment, more comprehensively demonstrates small peptide Arg-Arg-Tyr and influence of the glabridin to SD mouse skins.Knot
Fruit display small peptide Arg-Arg-Tyr has no toxic side effect to normal SD mouse skin histology, can for skin safe
Lean on.
Trp or Phe is added on the basis of small peptide Arg-Arg-Tyr, can be reached same or similar
Effect, with the effect of Arg-Arg-Tyr without significant difference.
The preparation of the cosmetics of embodiment 4
Acceptable auxiliary material is obtained cosmetic according to customary preparation methods in taking Arg-Arg-Tyr peptides addition cosmetics
Product.The cosmetics refer to smear, spray or other similar approach, impose on human body surface (such as epidermis,
Hair, nail, lip etc.), play cleaning, maintenance, beautification or eliminate the product of bad smell effect,
The product using position to that can have abirritation.
The formulation of the cosmetics is liquid, mellite, milk agent, paste, creme, pulvis, bulk, rod
One or more in shape.
The concentration of the peptide is 0.01-100 μM.
The inspection of the cosmetics of embodiment 5
Cosmetics prepared by embodiment 3 are tested according to cosmetics national standard, as a result such as table 4:
The cosmetics test stone of table 4 and result
Result above shows that the obtained cosmetics of the present invention meet the phase of National Standard of the People's Republic of China
Close regulation.
The above is only the preferred embodiment of the present invention, it is noted that general for the art
For logical technical staff, under the premise without departing from the principles of the invention, some improvement and profit can also be made
Decorations, these improvements and modifications also should be regarded as protection scope of the present invention.
Claims (9)
1. a kind of peptide, it is characterised in that it includes:
(I), the amino acid sequence of Arg-Arg-Tyr;Or
(II), (I) described amino acid sequence is substituted, lacks or adds one or more amino acid and obtains
Amino acid sequence, and with the same or analogous amino acid sequence of amino acid sequence function shown in (I)
Row;
(III) and (I) or (II) described sequence at least 80% homology amino acid sequence;
The amino acid number of the peptide is 3~5.
2. peptide according to claim 1, it is characterised in that the amino acid of the addition is selected from Trp
Or Phe.
3. peptide according to claim 1 and 2 is preparing the cosmetics for preventing and/or treating aging
In application.
4. application according to claim 3, it is characterised in that the aging is skin senescence.
5. the application according to claim 3 or 4, it is characterised in that the effective dose of described peptide
It is 0.01-100 μM.
6. the application according to any one of claim 3 to 5, it is characterised in that the cosmetics
Formulation be aqua, mellite, milk agent, paste, creme, pulvis, bulk, it is bar-shaped in one or more.
7. a kind of cosmetics, it is characterised in that including peptide as claimed in claim 1 or 2.
8. cosmetics according to claim 7, it is characterised in that the effective dose of described peptide is
0.01-100μM。
9. cosmetics according to claim 7 or 8, it is characterised in that its formulation is aqua, honey
Agent, milk agent, paste, creme, pulvis, bulk, it is bar-shaped in one or more.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510847635.XA CN106800588A (en) | 2015-11-26 | 2015-11-26 | A kind of peptide and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510847635.XA CN106800588A (en) | 2015-11-26 | 2015-11-26 | A kind of peptide and its application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106800588A true CN106800588A (en) | 2017-06-06 |
Family
ID=58976866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510847635.XA Withdrawn CN106800588A (en) | 2015-11-26 | 2015-11-26 | A kind of peptide and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106800588A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008106491A2 (en) * | 2007-02-27 | 2008-09-04 | University Of Utah Research Foundation | Peptides that interact with topoisomerase i and methods thereof |
CN104324359A (en) * | 2014-09-25 | 2015-02-04 | 中山大学 | Application of RRY tripeptide in preparation of drug for treating Alzheimer's disease |
-
2015
- 2015-11-26 CN CN201510847635.XA patent/CN106800588A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008106491A2 (en) * | 2007-02-27 | 2008-09-04 | University Of Utah Research Foundation | Peptides that interact with topoisomerase i and methods thereof |
CN104324359A (en) * | 2014-09-25 | 2015-02-04 | 中山大学 | Application of RRY tripeptide in preparation of drug for treating Alzheimer's disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Huxley et al. | The elements of experimental embryology | |
CN103889397B (en) | Cosmetic composition containing green tea component | |
CN105326697B (en) | A kind of 3D printing method for nursing film | |
Graham-Brown et al. | Dermatology | |
BRPI0518953B1 (en) | COMPOSITIONS AND METHODS OF USE TO IMPROVE SKIN CONDITION AND APPEARANCE | |
CN101969917A (en) | Anti-wrinkle composition and external skin composition | |
CN105943466B (en) | A kind of baby child's shampoo used also as bath lotion | |
CN103320490A (en) | Screening method of safety and efficacy of skin antioxidants through use of a plurality of normal human skin cells | |
CN109152727A (en) | Peptide and sugar hydrolysate, the cosmetic use containing its cosmetic composition and the cosmetic composition of cocoa bean | |
CN109846787A (en) | A kind of composition and its application in the cosmetics that skin physiology and/or biochemical structure are repaired in preparation | |
CN114317661B (en) | Method for preparing multiple active collagen | |
CN105709265A (en) | Novel porous hemostatic material and preparation method thereof | |
CN106983698A (en) | A kind of composition for suppressing epidermis grease and the cosmetics being made from it | |
CN110302091A (en) | A kind of anti aging effect composition of niacinamide-containing adenine-dinucleotide and its preparation method and application | |
CN109771352A (en) | It is a kind of repair skin composition and its preparation cosmetics | |
CN108473951A (en) | Method for producing hair follicle and newborn nipple and its for the purposes of testing in vitro and implants in vivo | |
CN107115220A (en) | A kind of activity of fighting against senium compositions and preparation method and application | |
CN106800588A (en) | A kind of peptide and its application | |
CN110339104A (en) | A kind of anti-alopecia composition and preparation method | |
CN106109385A (en) | A kind of natural essence being prone to absorb | |
CN106995795A (en) | Cellular processes, kit and freeze-dried powder based on platelet rich plasma | |
CN106798654A (en) | The application of glabridin | |
CN103040943A (en) | Chinese medicinal liniment for treating premature graying of youngsters | |
CN104922700A (en) | Experimental method for applying Sirt1-Nrf2 novel oxidation resisting pathway in oxidative damage treatment | |
CN109939129A (en) | A kind of application of pearl mother liquor in preparation cell repair product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170606 |
|
WW01 | Invention patent application withdrawn after publication |